Showing results (251-260 of 447) with videos related to
Sort By:
Pageof 45
Clinical Proteomics|May 5, 2012
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor TissueTodd Hembrough, Sheeno Thyparambil, Wei-Li Liao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2008
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, et al.Clinical Trials (London, England)|January 3, 2020
Trial marketing in the Pan-Canadian Early Detection of Lung Cancer StudyJanice L Rudkowski, Gregory R Pond, Alain Tremblay, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 ClassificationJennifer L Sauter, Sanja Dacic, Francoise Galateau-Salle, et al.Clinical Lung Cancer|July 12, 2023
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio DataPrashanth Ashok Kumar, Maryam Karimi, Alina Basnet, et al.BMC Pulmonary Medicine|November 17, 2020
Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening populationJohn R Goffin, Gregory R Pond, Serge Puksa, et al.Chest|March 5, 2021
Risk Perception Among a Lung Cancer Screening PopulationJane Turner, Gregory R Pond, Alain Tremblay, et al.Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancerKevin Jao, Pascale Tomasini, Suzanne Kamel-Reid, et al.British Journal of Cancer|October 11, 2025
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanismsJoshua C Rosen, Pinjiang Cao, Nhu-An Pham, et al.Oncotarget|October 21, 2017
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, et al.Pageof 45